UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB/A
(AMENDMENT NO. 1)
QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTER ENDED JULY 31, 2003
ENHANCE BIOTECH, INC.
(FORMERLY BECOR COMMUNICATIONS, INC.,
A DEVELOPMENT STAGE COMPANY)
(Exact name of registrant as specified in its charter)
Delaware 000-31653 95-4766094
- ------------------------------- ---------- ----------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File No.) Identification No.)
1285 Avenue of the Americas, 35th Floor, New York, NY 10019
- ------------------------------------------------------- -----------
(Address of principal executive offices) (Zip Code)
Issuer's telephone number, including area code: (212) 561-1716
---------------
Check whether the registrant: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [_]
Class Outstanding at August 31, 2003
----- ------------------------------
Common stock, $0.001 par value 16,128,900
AMENDMENT NO. 1
TO THE QUARTERLY REPORT ON FORM 10-QSB FILED BY
ENHANCE BIOTECH, INC. ON SEPTEMBER 15, 2003
The Quarterly Report on Form 10QSB filed by Enhance Biotech, Inc., on
September 15, 2003, is hereby amended, as permitted by the rules and regulations
promulgated by the Securities and Exchange Commission, to include Exhibits 10.1
and 10.2 as listed in Item 6 below. Besides the addition of these exhibits, no
other changes have been made to the Form 10-QSB for the period ended July 31,
2003.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
The company filed one report on Form 8-K/A during the quarter ended July 31,
2003, and one report on Form 8-K subsequent to July 31, 2003, but prior to the
filing of this Form 10-QSB. Information regarding the items reported on is as
follows:
Date Item Reported On
----------------- -----------------------------------------
July 14, 2003 Acquisition of Enhance Lifesciences, Inc.
September 4, 2003 Change in accountants
10.1 Co-Development Agreement between DMI BioSciences, Inc. and Registrant
in regards to DMI 7958.
10.2 Co-Development Agreement between DMI BioSciences, Ic. and Registrant in
regards to DMI 9742.
31.1 Certification of CEO Pursuant to Securities Exchange Act Rules 13a-14
and 15d-14, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
31.2 Certification of CFO Pursuant to Securities Exchange Act Rules 13a-14
and 15d-14, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned.
Enhance Biotech, Inc.
Date: September 16, 2003 By: /s/ Linden Boyne
----------------------------
Linden Boyne
Chief Financial Officer
(Principal Financial and
Accounting Officer and Duly
Authorized Officer)
3